Literature DB >> 18595137

Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulations in chronic HBV-infected individuals with normal liver function tests.

Jing You1, Hutcha Sriplung, Alan Geater, Virasakdi Chongsuvivatwong, Lin Zhuang, Hong-Ying Chen, Jun-Hua Huang, Bao-Zhang Tang.   

Abstract

AIM: To investigate the peripheral T-lymphocyte subpopulation profile, and its correlations with hepatitis B virus (HBV) replication level in chronic HBV-infected (CHI) individuals with normal liver function tests (LFTs).
METHODS: Frequencies of T-lymphocyte subpopulations in peripheral blood were measured by flow cytometry in 216 CHI individuals. HBV markers were detected with ELISA. Serum HBV DNA load was assessed with quantitative real-time PCR. Information of age at HBV infection, and maternal HBV infection status was collected. ANOVA linear trend test and linear regression were used in statistical analysis.
RESULTS: CHI individuals had significantly decreased relative frequencies of CD3(+), CD4(+) subpopulations and CD4(+)/CD8(+) ratio, and increased CD8(+) subset percentage compared with uninfected individuals (all P < 0.001). There was a significant linear relationship between the load of HBV DNA and the parameters of T-lymphocyte subpopulations (ANOVA linear trend test P < 0.01). The parameters were also significantly worse among individuals whose mothers were known to be HBV carriers, and those having gained infection before the age of 8 years. In multiple regressions, after adjustment for age at HBV infection and status of maternal HBV infection, log copies of HBV DNA maintained its highly significant predictive coefficient on T-lymphocyte subpopulations, whereas the effect of HBeAg was not significant.
CONCLUSION: HBV DNA correlates with modification in the relative T-lymphocyte subpopulation frequencies. High viral load is more powerful than HBeAg in predicting the impaired balance of T-cell subsets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18595137      PMCID: PMC2719233          DOI: 10.3748/wjg.14.3710

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

1.  A new hypothesis of pathogenetic mechanism of viral hepatitis B and C.

Authors:  D X Liu
Journal:  Med Hypotheses       Date:  2001-03       Impact factor: 1.538

Review 2.  Pathogenesis of hepatitis B virus infection.

Authors:  Thomas F Baumert; Robert Thimme; Fritz von Weizsäcker
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 3.  Vaccination and autoimmunity-'vaccinosis': a dangerous liaison?

Authors:  Y Shoenfeld; A Aron-Maor
Journal:  J Autoimmun       Date:  2000-02       Impact factor: 7.094

4.  Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection.

Authors:  T I Michalak; P D Hodgson; N D Churchill
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection.

Authors:  M Chen; M Sällberg; S N Thung; J Hughes; J Jones; D R Milich
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Authors:  G J Webster; S Reignat; M K Maini; S A Whalley; G S Ogg; A King; D Brown; P L Amlot; R Williams; D Vergani; G M Dusheiko; A Bertoletti
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

7.  Mutation at codon 130 in hepatitis B virus (HBV) core region increases markedly during acute exacerbation of hepatitis in chronic HBV carriers.

Authors:  A Okumura; T Ishikawa; K Yoshioka; R Yuasa; Y Fukuzawa; S Kakumu
Journal:  J Gastroenterol       Date:  2001-02       Impact factor: 7.527

8.  Epidemiology of hepatitis B virus infection in the Asia-Pacific region.

Authors:  C J Chen; L Y Wang; M W Yu
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

9.  A molecular comparison of T lymphocyte populations infiltrating the liver and circulating in the blood of patients with chronic hepatitis B: evidence for antigen-driven selection of a public complementarity-determining region 3 (CDR3) motif.

Authors:  G K Sing; D Li; X Chen; T Macnaughton; A M Lichanska; L Butterworth; A Ladhams; G Cooksley
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

10.  Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

Authors:  C Boni; A Penna; G S Ogg; A Bertoletti; M Pilli; C Cavallo; A Cavalli; S Urbani; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

View more
  4 in total

1.  Impaired antigen processing and presentation machinery is associated with immunotolerant state in chronic hepatitis B virus infection.

Authors:  Sukriti Sukriti; Nirupma Trehan Pati; Sujoy Bose; Syed S Hissar; Shiv Kumar Sarin
Journal:  J Clin Immunol       Date:  2010-03-19       Impact factor: 8.317

2.  Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.

Authors:  John Idoko; Seema Meloni; Mohammed Muazu; Ladep Nimzing; Bitrus Badung; Claudia Hawkins; Jean-Louis Sankalé; Ernest Ekong; Robert Murphy; Phyllis Kanki; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

3.  Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa.

Authors:  C J Hoffmann; D Dayal; M Cheyip; J A McIntyre; G E Gray; S Conway; N A Martinson
Journal:  Int J STD AIDS       Date:  2012-10       Impact factor: 1.359

4.  Frequencies of dendritic cells and Toll-like receptor 3 in neonates born to HBsAg-positive mothers with different HBV serological profiles.

Authors:  J Guo; Y Gao; Z Guo; L R Zhang; B Wang; S P Wang
Journal:  Epidemiol Infect       Date:  2014-03-20       Impact factor: 4.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.